Journal article
Medical management of heavy menstrual bleeding: a comprehensive review of the literature.
- Bitzer J Professor, Chairman of Department, Department of Obstetrics and Gynecology, University Hospital of Basel, Basel, Switzerland.
- Heikinheimo O Professor, University of Helsinki, Department of Obstetrics and Gynaecology, and Helsinki University Central Hospital, Kätilöopisto Hospital, Helsinki, Finland.
- Nelson AL Professor, Los Angeles BioMedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA.
- Calaf-Alsina J Professor, Head of Department, Department of Obstetrics and Gynaecology, Hospital de la Santa Creu i Sant Pau, Universitat Autónoma, Barcelona, Spain.
- Fraser IS Professor in Reproductive Medicine, Department of Obstetrics and Gynaecology, Elizabeth II Research Institute for Mothers & Infants, University of Sydney, Sydney, New South Wales, Australia.
- 2015-02-12
Published in:
- Obstetrical & gynecological survey. - 2015
Anti-Inflammatory Agents, Non-Steroidal
Antifibrinolytic Agents
Contraceptives, Oral, Hormonal
Female
Humans
Intrauterine Devices, Medicated
Levonorgestrel
Menorrhagia
Progestins
Tranexamic Acid
English
IMPORTANCE
Heavy menstrual bleeding (HMB) is a common complaint among reproductive-aged women, which negatively affects their health as well as their social, professional, and family lives. Modern medical management usually provides effective control of HMB irrespective of the underlying cause. Surgical interventions should be reserved for women with significant pelvic pathology and those unresponsive to medical therapy.
OBJECTIVE
The aim of this review was to provide a comprehensive summary of the efficacy and safety of available medical treatments of HMB.
EVIDENCE ACQUISITION
A comprehensive MEDLINE and EMBASE literature search was undertaken using selected terms associated with HMB to identify clinical studies published before March 20, 2013, that reported changes in menstrual blood loss in women receiving medical intervention.
RESULTS
The effectiveness of treatments to reduce HMB due to endometrial dysfunction in descending order was as follows: (1) the levonorgestrel-releasing intrauterine system (LNG-IUS) (initial release rate of 20 μg of LNG per 24 hours), (2) combined hormonal contraceptives (oral or transvaginal), (3) tranexamic acid, and (4) long-course oral progestogens (≥3 weeks per cycle). The LNG-IUS was found to reduce HMB due to some structural causes (leiomyomas and adenomyosis). The reduction in menstrual blood loss achieved with nonsteroidal anti-inflammatory drugs and short-course oral progestogens (≤14 days per cycle) is less impressive but may be sufficient for women who have marginally increased blood loss.
CONCLUSIONS AND RELEVANCE
For women not seeking pregnancy, the LNG-IUS is the first-line medical therapy for HMB, with combined hormonal contraceptives as second choice. For other women, fewer effective options exist.
Heavy menstrual bleeding (HMB) is a common complaint among reproductive-aged women, which negatively affects their health as well as their social, professional, and family lives. Modern medical management usually provides effective control of HMB irrespective of the underlying cause. Surgical interventions should be reserved for women with significant pelvic pathology and those unresponsive to medical therapy.
OBJECTIVE
The aim of this review was to provide a comprehensive summary of the efficacy and safety of available medical treatments of HMB.
EVIDENCE ACQUISITION
A comprehensive MEDLINE and EMBASE literature search was undertaken using selected terms associated with HMB to identify clinical studies published before March 20, 2013, that reported changes in menstrual blood loss in women receiving medical intervention.
RESULTS
The effectiveness of treatments to reduce HMB due to endometrial dysfunction in descending order was as follows: (1) the levonorgestrel-releasing intrauterine system (LNG-IUS) (initial release rate of 20 μg of LNG per 24 hours), (2) combined hormonal contraceptives (oral or transvaginal), (3) tranexamic acid, and (4) long-course oral progestogens (≥3 weeks per cycle). The LNG-IUS was found to reduce HMB due to some structural causes (leiomyomas and adenomyosis). The reduction in menstrual blood loss achieved with nonsteroidal anti-inflammatory drugs and short-course oral progestogens (≤14 days per cycle) is less impressive but may be sufficient for women who have marginally increased blood loss.
CONCLUSIONS AND RELEVANCE
For women not seeking pregnancy, the LNG-IUS is the first-line medical therapy for HMB, with combined hormonal contraceptives as second choice. For other women, fewer effective options exist.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1097/OGX.0000000000000155
- PMID 25671373
- Persistent URL
- https://sonar.ch/global/documents/49417
Statistics
Document views: 54
File downloads: